Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue, ₹2,181m EBITDA, and ₹1,140m Operational PAT".
Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue, ₹2,181m EBITDA, and ₹1,140m Operational PAT".